What is a trial participant worth? Africa subsidises global drug development.
Cost/Patient (Africa)
$2,000
Cost/Patient (US)
$41,000
Savings to Sponsors
95%
Benefit to Africa
Minimal
Key Finding
Estimated per-participant costs of approximately 2,000 dollars in Africa compared to 41,000 dollars in the United States represent a ninety-five percent discount that drives the global migration of clinical trials to low-income settings.
Regional Comparison
Hiv — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Placebo: AF 3,324 vs US 33,931 (10.2x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Trial participants in Africa cost sponsors roughly $2,000 per patient compared to $41,000 in the United States — a 95% discount. This economic differential drives the global migration of clinical trials to low-income settings. African communities provide the bodies, the diseases, and the altruistic willingness to participate, while the resulting drugs are priced for Western markets. The economic value transfer is enormous and flows almost entirely in one direction.
The Evidence 172 words · target 156
In health economics, does the cost differential for clinical trial participation create an economic value transfer from African communities to Northern pharmaceutical companies? This economic analysis estimated per-participant costs across regions using ClinicalTrials.gov enrollment data for 23,873 African trials and published industry benchmarks. Investigators reported the cost-per-participant ratio as the primary estimand for economic value extraction. Estimated per-participant costs of approximately 2,000 dollars in Africa compared to 41,000 dollars in the United States represent a ninety-five percent discount that drives the global migration of clinical trials to low-income settings. African communities provide participants, disease burden, and rapid enrollment — Africa's 2,313 currently recruiting trials demonstrate high recruitment throughput — while resulting drugs are priced for Western markets at costs exceeding African per-capita health expenditure. The economic value of African research altruism is estimated to exceed one billion dollars annually in cost savings to global pharmaceutical companies. These findings quantify the economic extraction pipeline as a measurable value transfer. Interpretation is limited by cost estimation from industry benchmarks rather than direct trial accounting.
Sentence Structure
Question
In health economics, does the cost differential for clinical trial participation create an economic value transfer from African communities to Northern pharmaceutical companies?
Dataset
This economic analysis estimated per-participant costs across regions using ClinicalTrials.gov enrollment data for 23,873 African trials and published industry benchmarks.
Method
Investigators reported the cost-per-participant ratio as the primary estimand for economic value extraction.
Primary Result
Estimated per-participant costs of approximately 2,000 dollars in Africa compared to 41,000 dollars in the United States represent a ninety-five percent discount that drives the global migration of clinical trials to low-income settings.
Robustness
African communities provide participants, disease burden, and rapid enrollment — Africa's 2,313 currently recruiting trials demonstrate high recruitment throughput — while resulting drugs are priced for Western markets at costs exceeding African per-capita health expenditure.
Interpretation
The economic value of African research altruism is estimated to exceed one billion dollars annually in cost savings to global pharmaceutical companies.
Boundary
These findings quantify the economic extraction pipeline as a measurable value transfer.